Literature DB >> 10667492

Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins.

E E Douzinas1, M T Pitaridis, G Louris, I Andrianakis, K Katsouyanni, D Karmpaliotis, J Economidou, D Syfras, C Roussos.   

Abstract

OBJECTIVE: To investigate the activity of intravenous immunoglobulin (IVIG) as a prophylactic agent against infection in trauma victims.
DESIGN: Prospective, randomized, double-blind, placebo-controlled study.
SETTING: A 20-bed university intensive care unit. PATIENTS: Thirty-nine trauma patients with injury severity scores (ISSs) of 16-50.
INTERVENTIONS: Penicillin was given at the time of admission and continued at least until day 4. Twenty-one patients received IVIG and 18 patients received human albumin at 1 g/kg in four divided doses (days 1, 2, 3, and 6). The two groups had similarities in age, gender, Acute Physiology and Chronic Health Evaluation II score, risk of death, and Glasgow Coma Scale score, but differing ISSs (p = .02), at the time of admission. Blood was collected on days 1, 4, and 7.
MEASUREMENTS AND MAIN RESULTS: Clinical variables related to infection were recorded. The complement components C3c, C4 and CH50, IgG, and the fractions of IgG were measured. The serum bactericidal activity (SBA) was assessed at 37 degrees C (98.6 degrees F) and 40 degrees C (104.0 degrees F) at the time of admission and during the course of IVIG administration. Controlling for ISS, IVIG-treated patients had fewer pneumonias (p = .003) and total non-catheter-related infections (p = .04). Catheter-related infections (p = .76), length of stay in the intensive care unit, antibiotic days, and infection-related mortality did not differ between the two groups. A significantly increased trend in IgG and its subclasses was shown on days 4 and 7 in the IVIG group but not in the control group (p<.000001). No important differences were noted in complement fractions. The SBA of the groups was similar on day 1, but significantly higher on days 4 and 7 (p<.000001) in the IVIG group, remaining so controlling for complement and ISS. SBA was higher at 40 degrees C (104.0 degrees F) compared with 37 degrees C (98.6 degrees F) (p<.0001) under all three conditions. In both groups, low SBA (on days 1, 4, and 7) was associated with increased risk of pneumonia (p<.01) and non-catheter-related infections (p = .06 for day 1; p<.01 for days 4 and 7).
CONCLUSIONS: Trauma patients receiving high doses of IVIG exhibit a reduction of septic complications and an improvement of SBA. Early SBA measurement may represent an index of susceptibility to infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667492     DOI: 10.1097/00003246-200001000-00002

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  11 in total

Review 1.  Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases.

Authors:  V G Hemming
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  Recommendations for the use of albumin and immunoglobulins.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossettias
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

Review 3.  The implications and management of septic acute kidney injury.

Authors:  Zaccaria Ricci; Andrea Polito; Angelo Polito; Claudio Ronco
Journal:  Nat Rev Nephrol       Date:  2011-03-01       Impact factor: 28.314

Review 4.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

5.  Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo.

Authors:  N Farag; L Mahran; K Abou-Aisha; M El-Azizi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-03-27       Impact factor: 3.267

6.  Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults.

Authors:  Kevin B Laupland
Journal:  Can J Infect Dis       Date:  2002-03

Review 7.  A systematic review of randomized controlled trials exploring the effect of immunomodulative interventions on infection, organ failure, and mortality in trauma patients.

Authors:  Nicole E Spruijt; Tjaakje Visser; Luke Ph Leenen
Journal:  Crit Care       Date:  2010-08-05       Impact factor: 9.097

Review 8.  Late immune consequences of combat trauma: a review of trauma-related immune dysfunction and potential therapies.

Authors:  Kelly B Thompson; Luke T Krispinsky; Ryan J Stark
Journal:  Mil Med Res       Date:  2019-04-24

Review 9.  The systemic immune response to trauma: an overview of pathophysiology and treatment.

Authors:  Janet M Lord; Mark J Midwinter; Yen-Fu Chen; Antonio Belli; Karim Brohi; Elizabeth J Kovacs; Leo Koenderman; Paul Kubes; Richard J Lilford
Journal:  Lancet       Date:  2014-10-17       Impact factor: 79.321

Review 10.  Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Trends Pharmacol Sci       Date:  2004-06       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.